5 results
The primary objective of the present study is to assess the feasibility and safety of a newly developed PET-guided breast biopsy system in breast cancer patients.
To evaluate the safety and efficacy of PRX-102 compared to agalsidase beta in Fabry disease patients with impaired renal function.
To evaluate the ongoing safety, tolerability, and efficacy parameters of pegunigalsidase alfa in adult Fabry patients who have successfully completed studies PB-102-F20 and PB-102-F30, or completed at least 48 months in study PB-102-F03.
The most important purpose of this scientific study is to determine whether the use of tivantinib is safe and effective in patients with liver cancer in which the MET-protein is present in high concentration.
To evaluate the safety and efficacy of PRX-102 in patients with Fabry disease currently treated with agalsidase alfa